Company Overview
Bausch + Lomb Corporation operates as a global eye health company with a significant physical presence across the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and various international markets. The business is structured into three primary segments: Vision Care, Pharmaceuticals, and Surgical, allowing it to address diverse needs within the medical and consumer eye health markets. This entity functions within the Healthcare sector, specifically classified under the Medical Instruments & Supplies industry, which positions it as a supplier of essential diagnostic tools, therapeutic devices, and pharmaceutical solutions required for patient care. In terms of scale, the company carries a market capitalization of $5.74B and reports annual revenue of $5.10B, supported by a workforce of 13000 employees. These financial dimensions indicate that the company maintains a mid-to-large capitalization status within its industry, suggesting a substantial operational footprint capable of sustaining significant R&D and distribution networks while navigating the complexities of global regulatory environments.
Financial Health
The company reported revenue of $5.10B for the trailing twelve months, yet recorded a net income of $-360,000,000, creating a substantial gap that reveals a cost structure where expenses significantly exceeded total revenues during this period. Despite the negative net income, the company generated an EBITDA of $609.00M, highlighting that earnings before interest, taxes, depreciation, and amortization remained robust enough to cover operating costs before financing charges. The balance sheet shows a cash position of $383.00M against total debt of $5.25B, resulting in a debt-to-equity ratio of 80.46, which indicates a highly leveraged balance sheet where interest obligations are a primary driver of the reported losses. Profitability metrics further illustrate this strain, with a gross margin of 59.8% demonstrating strong pricing power or product mix, contrasted by an operating margin of 11.2% and a negative profit margin of -7.1%. Liquidity is supported by a current ratio of 1.55, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. However, the return on equity stands at -5.4% and the return on assets is 0.9%, metrics that collectively reveal that management effectiveness has been challenged by the recent period of earnings depletion and high leverage.
Valuation Assessment
Valuation metrics for Bausch + Lomb present a complex picture, with a trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E is 15.27. The divergence between the unavailable trailing P/E and the forward P/E implies that the market is pricing in a significant expected recovery in earnings trajectory over the coming year. The price-to-book ratio is 0.89, which indicates that the market values the company at a discount to its book value, suggesting a lack of market premium over the net asset value held on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 1.13 and an EV/EBITDA of 17.51 suggest that despite current earnings struggles, the company is valued relative to its sales volume and cash generation potential. The stock has traded between a 52-week high of $18.91 and a 52-week low of $10.45, placing the current valuation context within this established historical range. The beta value of 0.58 indicates that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the general index during periods of market fluctuation.
Growth & Income
Revenue growth for the trailing twelve months stands at 9.8%, whereas earnings growth is listed as N/A due to the negative net income position. This disparity implies that while top-line sales are expanding, the bottom line has not yet followed suit, suggesting that cost reductions or margin expansion are required to translate revenue gains into actual profitability. Regarding income distributions, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividends means the company retains all earnings, if any, to reinvest into operations or reduce its substantial debt load rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by solid revenue expansion paired with a complete lack of current income yield, relying entirely on potential future earnings recovery to generate shareholder value.